B
Bull
Bull · 25%IBO
$0.65
Scenario price
$0.458
-0.003 (-0.68%)At close
Loading chart…
- High
- 0.490
- Open
- 0.483
- VWAP
- 0.47
- Vol
- 26.68K
- Mkt Cap
- —
- Low
- 0.456
- Amount
- 12.48K
- EV/EBITDA, TTM
- 0.00
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
AI analysis of Impact Biomedical Inc (IBO)
sellImpact Biomedical Inc is not a good buy right now due to its current price of 0.4437 and a declining trend in revenue, with total revenue of only 18,000 USD in Q3 2025. Additionally, the company has a concerning 'going concern' qualification in its annual report, which raises significant risks for investors.
Valuation Metrics
The current forward P/E ratio for Impact Biomedical Inc (IBO) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for IBO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
5.004-29moomooInsider at Impact BioMedical (IBO.US) Plans to Sell $23.06 Million in Common Stock via Form 144
8.504-03NewsfilterImpact BioMedical Files Annual Report with Going Concern Qualification
9.504-03Yahoo FinanceImpact BioMedical Issues Annual Report with Going Concern Qualification
8.503-05NASDAQ.COMImpact BioMedical Shares Surge 115% After Merger Agreement Amendments
4.503-05BenzingaU.S. Stocks Decline as Kroger Reports Mixed Q4 Results
IBO FAQ — answered by Alphio AI
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies. It operates in the Healthcare sector.
Impact Biomedical Inc is not a good buy right now due to its current price of 0.4437 and a declining trend in revenue, with total revenue of only 18,000 USD in Q3 2025. Additionally, the company has a concerning 'going concern' qualification in its annual report, which raises significant risks for investors.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.